Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Astefania: Adjuvant atezolizumab plus trastuzumab emtansine vs placebo plus trastuzumab emtansine in high-risk HER2-positive early breast cancer
2023-503568-18-00Phase 3Authorised
- Sponsor
- Roche
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 32
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Tecentriq + Kadcyla with Placebo + Kadcyla (2 arms). Primary endpoint: Invasive disease-free survival. Planned start Apr 2021; status: authorised.
02
Drugs
atezolizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-503568-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503568-18-00.